MPO and ganglioneuroma: However, it is unclear whether the poorer prognoses associated with MPO- as compared to PR3-ANCA-GN are caused by more advanced disease at baseline [7, 8, 21–24] or due to differences in the nature of inflammation associated with these 2 different autoantibody serotypes [25–27].